Get the Stockscreener App
1.73
6.79%
0.11
After Hours:
1.86
0.13
+7.51%
Inmune Bio Inc stock is traded at $1.73, with a volume of 179.18K.
It is up +6.79% in the last 24 hours and up +21.83% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$1.62
Open:
$1.63
24h Volume:
179.18K
Relative Volume:
0.25
Market Cap:
$45.99M
Revenue:
$50,000
Net Income/Loss:
$-41.60M
P/E Ratio:
-1.0209
EPS:
-1.6946
Net Cash Flow:
$-20.20M
1W Performance:
-13.07%
1M Performance:
+21.83%
6M Performance:
-3.89%
1Y Performance:
-36.16%
1-Day Range:
$1.63
$1.75
1-Week Range:
$1.61
$2.04
52-Week Range:
$1.09
$3.244
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.73 | 43.07M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
INMB|INmune Bio Inc|Price:1.620|Chg%:-0.100 - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inmune Bio stock trades on Nasdaq as investors watch trial progress and cash runway - Ad-hoc-news.de
INMB Achieves Breakthrough in Umbilical Cord Tissue Processing - GuruFocus
INmune Bio And 2 Other Promising Penny Stocks To Consider - webull.com
INmune Bio Achieves Commercial-Ready Manufacturing Milestone for CORDStrom Platform Ahead of Planned Phase 3 Trial - Quiver Quantitative
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform - The Manila Times
INmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trial - Stock Titan
INmune Bio reports press release available - Bitget
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio publishes preclinical study on brain injury link to Alzheimer’s - Investing.com
INmune Bio Study Finds Soluble TNF Inhibition with XPro1595 Prevents TBI-Driven Amyloid Pathology in Alzheimer’s Model - Quiver Quantitative
In mice, XPro1595 prevented amyloid rise after brain injury - Stock Titan
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Reports Positive Phase 2 XPro Data - t.co
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's disease at AAIC - marketscreener.com
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8 - Moomoo
INmune Bio reports imaging data from Alzheimer’s drug trial By Investing.com - Investing.com Nigeria
INmune Bio reports imaging data from Alzheimer’s drug trial - Investing.com
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC - The Manila Times
INmune Bio Reports Concordant MRI Biomarker Changes Supporting Early XPro Treatment Activity in Phase 2 Alzheimer’s Study - Quiver Quantitative
INmune Bio says XPro imaging data at AAIC show early Alzheimer’s brain changes - Stock Titan
Form 4 INmune Bio Inc For: 7 July By Investing.com - Investing.com South Africa
Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
Inmune Bio (INMB) CEO exercises 9,014 April 2024 warrants at $1.40 - Stock Titan
Price to book forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc. (INMB) Edges Higher, Testing Key Resistance Amid Low-Volume TradingIV Spike - dars.gov.et
Enterprise value to revenue forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Inmune Bio Inc outlines its immunotherapy focus as shares trade on Nasdaq - Ad-hoc-news.de
Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - 富途牛牛
Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth? - Sahm
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
INmune Bio Executes Warrant Inducement and Extension Agreement - TipRanks
INMB Seeks Patent Approval for CORDStrom Platform - GuruFocus
INmune Bio files U.S. patent for cell therapy platform By Investing.com - Investing.com South Africa
INmune Bio files U.S. patent for cell therapy platform - Investing.com
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion - The Manila Times
INmune Bio moves CORDStrom into U.S. patent review - Stock Titan
Price to sales forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio (INMB) Proxy filing Summary - Quartr
Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM:INMB) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):